MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1080/14779072.2024.2387678

Медицинская библиотека · Expert review of cardiovascular therapy · 2024

Lipoprotein(a) in interventional cardiology: identifying patients at highest risk of recurrent cardiovascular events through early recognition - a case based review.

Renkens Mick P L, Coerkamp Casper F, Witte Lars S, Sivanesan Shabiga, Nurmohamed Nick S, Westerterp Marit, Serruys Patrick, Onuma Yoshinobu, Grundeken Maik J, Kalkman Deborah N, Beijk Marcel, Vis Marije M, Henriques José P S, Delewi Ronak, Stroes Erik, Wykrzykowska Joanna J, de Winter Robbert J, Claessen Bimmer E P M

СтатьяОбзорКлинический случайПеревод пока не подготовлен

Аннотация

INTRODUCTION

Lipoprotein(a) [Lp(a)] is linked to higher risks of atherosclerotic cardiovascular disease (ASCVD). Current guideline recommendations are quite liberal on measuring Lp(a) (Class IIa, Level C), and may lead to underuse among (interventional) cardiologists.

AREAS COVERED: This case-based narrative review outlines four clinical cases of patients with elevated Lp(a) to illustrate its pathophysiological impact on coronary artery disease (CAD). The expert consensus statements from the American Heart Association (AHA) and European Atherosclerosis Society (EAS) served as the basis of this review. More recent publications, from 2023 to 2024, were accessed through the MEDLINE online library.

EXPERT OPINION: We highlighted the importance of routine Lp(a) measurement in identifying patients at high risk for atherosclerosis, necessitating potent risk mitigation. Measuring Lp(a) helps clinicians identify which patients are at highest residual risk, who require potent pharmacological treatment and special attention during catheter interventions. As noninvasive and advanced intravascular imaging modalities evolve, future catheterization laboratories will integrate advanced imaging, diagnostics, and treatment, facilitating tailored patient care. Knowing Lp(a) levels is crucial in this context. While Lp(a)-lowering drugs are currently investigated in clinical trials, it is of paramount importance to know Lp(a) levels and strive toward aggressive management of other modifiable risk factors in patients with elevated Lp(a) and established symptomatic CAD being diagnosed or treated in catheterization laboratories.

Для цитирования: Renkens Mick P L, Coerkamp Casper F, Witte Lars S, Sivanesan Shabiga, Nurmohamed Nick S, Westerterp Marit, Serruys Patrick, Onuma Yoshinobu, Grundeken Maik J, Kalkman Deborah N, Beijk Marcel, Vis Marije M, Henriques José P S, Delewi Ronak, Stroes Erik, Wykrzykowska Joanna J, de Winter Robbert J, Claessen Bimmer E P M. Lipoprotein(a) in interventional cardiology: identifying patients at highest risk of recurrent cardiovascular events through early recognition - a case based review.. Expert review of cardiovascular therapy. 2024. DOI: 10.1080/14779072.2024.2387678.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.